[go: up one dir, main page]

PE20230850A1 - Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico y un proceso para su preparacion - Google Patents

Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico y un proceso para su preparacion

Info

Publication number
PE20230850A1
PE20230850A1 PE2023001480A PE2023001480A PE20230850A1 PE 20230850 A1 PE20230850 A1 PE 20230850A1 PE 2023001480 A PE2023001480 A PE 2023001480A PE 2023001480 A PE2023001480 A PE 2023001480A PE 20230850 A1 PE20230850 A1 PE 20230850A1
Authority
PE
Peru
Prior art keywords
indol
pyrazole
cyano
isopropyl
carboxylic acid
Prior art date
Application number
PE2023001480A
Other languages
English (en)
Inventor
Seok Cheol Yoo
Joomyung Jang
Ree Sun Kim
Jin A Seo
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of PE20230850A1 publication Critical patent/PE20230850A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion esta referida a una formulacion oral caracterizada porque comprende un ingrediente farmaceutico activo (API) seleccionado de acido 1-(3-ciano-1-isopropil-indol-5- il)pirazol-4-carboxilico o una sal farmaceuticamente aceptable de este; y un fluidificante, en donde el fluidificante se selecciona del grupo que consiste en dioxido de silicio coloidal, dioxido de silicio hidratado y combinaciones de estos. Esta formulacion se emplea para inhibir la xantina oxidasa que puede prevenir la deposicion de acido urico en el cuerpo, y, por lo tanto, es util para tratar enfermedades relacionadas con la xantina oxidasa tales como hiperuricemia, gota, insuficiencia cardiaca, enfermedades cardiovasculares, tension arterial alta, diabetes, enfermedades renales, enfermedades de las articulaciones y enfermedad inflamatoria intestinal.
PE2023001480A 2020-12-01 2021-11-30 Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico y un proceso para su preparacion PE20230850A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200165790 2020-12-01
PCT/KR2021/017843 WO2022119270A1 (ko) 2020-12-01 2021-11-30 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산을 포함하는 경구용 제제, 및 그의 제조방법

Publications (1)

Publication Number Publication Date
PE20230850A1 true PE20230850A1 (es) 2023-05-23

Family

ID=81854229

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023001480A PE20230850A1 (es) 2020-12-01 2021-11-30 Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico y un proceso para su preparacion

Country Status (15)

Country Link
US (1) US20240173259A1 (es)
EP (1) EP4257124A4 (es)
JP (2) JP7618806B2 (es)
KR (1) KR102749901B1 (es)
CN (1) CN116528853A (es)
AR (1) AR124180A1 (es)
AU (1) AU2021392532B2 (es)
BR (1) BR112023009427A2 (es)
CA (1) CA3195598A1 (es)
CL (1) CL2023001061A1 (es)
CO (1) CO2023005206A2 (es)
MX (1) MX2023005461A (es)
PE (1) PE20230850A1 (es)
WO (1) WO2022119270A1 (es)
ZA (1) ZA202305155B (es)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
GB0209265D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
US20070042034A1 (en) * 2005-07-22 2007-02-22 Myriad Genetics, Incorporated High drug load formulations and dosage forms
SI2133332T1 (sl) * 2007-04-11 2014-02-28 Kissei Pharmaceutical Co., Ltd. (aza)indolinski derivat in njegova uporaba v medicinske namene
TWI423962B (zh) * 2009-10-07 2014-01-21 Lg Life Sciences Ltd 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物
WO2012050589A1 (en) * 2010-10-15 2012-04-19 Ardea Biosciences, Inc. Methods for treating hyperuricemia and related diseases
TWI548630B (zh) * 2011-04-06 2016-09-11 Ｌｇ生命科學有限公司 １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶型及其製造方法
WO2013001441A1 (en) * 2011-06-29 2013-01-03 Ranbaxy Laboratories Limited Dry formulations of febuxostat
EP2692342A1 (en) * 2012-07-30 2014-02-05 Interquim, S.A. Process for the preparation of pharmaceutical compositions comprising febuxostat in the form of tablets
JP2017081859A (ja) 2015-10-29 2017-05-18 共和薬品工業株式会社 テルミサルタン含有錠剤の製造方法
CN106880619A (zh) * 2015-12-15 2017-06-23 北大方正集团有限公司 一种托匹司他胶囊剂及其制备方法
JP6946609B2 (ja) 2017-06-08 2021-10-06 高田製薬株式会社 ブロナンセリン含有錠剤
JP2020117503A (ja) 2019-01-25 2020-08-06 株式会社東洋新薬 経口組成物
TW202509020A (zh) * 2020-11-04 2025-03-01 南韓商Ｌｇ化學股份有限公司 １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶之製備方法及包含彼之醫藥組成物

Also Published As

Publication number Publication date
EP4257124A1 (en) 2023-10-11
JP7618806B2 (ja) 2025-01-21
KR102749901B1 (ko) 2025-01-03
CL2023001061A1 (es) 2023-12-11
EP4257124A4 (en) 2024-05-29
WO2022119270A1 (ko) 2022-06-09
CN116528853A (zh) 2023-08-01
CA3195598A1 (en) 2022-06-09
AU2021392532B2 (en) 2025-04-10
CO2023005206A2 (es) 2023-04-27
JP2025039725A (ja) 2025-03-21
TW202231270A (zh) 2022-08-16
BR112023009427A2 (pt) 2024-02-06
KR20220077092A (ko) 2022-06-08
JP2023551524A (ja) 2023-12-08
AR124180A1 (es) 2023-02-22
MX2023005461A (es) 2023-05-22
ZA202305155B (en) 2024-09-25
AU2021392532A1 (en) 2023-06-29
US20240173259A1 (en) 2024-05-30

Similar Documents

Publication Publication Date Title
JP2013543492A5 (es)
AR079930A2 (es) Formulaciones de inhibidores de dipeptidil peptidasa iv (dpp iv)
US20240041857A1 (en) Pharmaceutical composition for treatment of aortic aneurysm
JP2023501221A (ja) バダデュスタットを使用する治療方法
PE20230850A1 (es) Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico y un proceso para su preparacion
PE20240222A1 (es) Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico y un proceso para su preparacion
ZA202308193B (en) Functionalized long-chain carboxylic acids, and their use for treatment of disease
JP2020514411A (ja) チオールイソメラーゼ阻害剤およびその使用
ZA202311241B (en) Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid
AU2018263059A1 (en) Compositions and treatment procedures for the treatment of pathogenic infections
PE20240764A1 (es) Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico
CN108601784A (zh) 药物
MX2024002863A (es) Medicina para la prevencion y tratamiento de enfermedades vinculadas a la actividad antiobesidad.
RU2011134414A (ru) Комбинация фульвовой кислоты для лечения различных состояний и болезней
EP2586442A1 (en) Sustained-release therapeutic agent for hypertension and renal dysfunction
Kalyuzhin et al. Promising directions in the treatment of chronic heart failure: improving old or developing new ones
EP4302787A1 (en) Hydroxyethycellulose gel compositions comprising bacteriophages
EP3842056B1 (en) Use of ghrp-6 as late cardioprotective and cardiac restoration medicament
BR112015024462A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, inibidor da xantina oxidase, e, agente terapêutico ou profilático para uma doença
Lehmann F et al. Compromiso cardiovascular en pacientes pediátricos en diálisis peritoneal crónica
US20230072496A1 (en) Polypeptide compositions and uses thereof
WO2025006940A2 (en) Compositions and methods for treating inflammatory bowel disease
Maki et al. Initial and programmed combination therapy with oral drugs for severe idiopathic pulmonary arterial hypertension
TH104398B (th) การใช้ยูเรตออกซิเดสเพื่อการรักษาหรือการป้องกันความผิดปกติหรือผลกระทบทางอ้อมที่ตามมาของหัวใจที่เกิดจากภาวะพร่องเลือดหรือผ่านเลือด
TH104398A (th) การใช้ยูเรตออกซิเดสเพื่อการรักษาหรือการป้องกันความผิดปกติหรือผลกระทบทางอ้อมที่ตามมาของหัวใจที่เกิดจากภาวะพร่องเลือดหรือผ่านเลือด